Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct 1;69(14):1911-34.
doi: 10.2165/11315680-000000000-00000.

Histone deacetylase inhibitors: current status and overview of recent clinical trials

Xujun Ma  1 , Hany H Ezzeldin, Robert B Diasio
Affiliations
Review

Histone deacetylase inhibitors: current status and overview of recent clinical trials

Xujun Ma et al. Drugs. .

Abstract

Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a potential role in the regulation of gene expression, induction of cell death, apoptosis and cell cycle arrest of cancer cells by altering the acetylation status of chromatin and other non-histone proteins. In clinical trials, HDAC inhibitors have demonstrated promising antitumour activity as monotherapy in cutaneous T-cell lymphoma and other haematological malignancies. In solid tumours, several HDAC inhibitors have been shown to be efficacious as single agents; however, results of most clinical trials were in favour of using HDAC inhibitors either prior to the initiation of chemotherapy or in combination with other treatments. Currently, the molecular basis of response to HDAC inhibitors in patients is not fully understood. In this review, we summarize the current status of HDAC inhibitors, as single agents or in combination with other agents in different phases of clinical trials. In most of the clinical trials, HDAC inhibitors were tolerable and exerted biological or antitumor activity. HDAC inhibitors have been studied in phase I, II and III clinical trials with variable efficacy. The combination of HDAC inhibitors with other anticancer agents including epigenetic or chemotherapeutic agents demonstrated favourable clinical outcome.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Med. 2001 Apr;7(4):437-43 - PubMed
    1. Mol Cancer Ther. 2005 Dec;4(12):1993-2000 - PubMed
    1. J Clin Endocrinol Metab. 2009 Jan;94(1):164-70 - PubMed
    1. Mol Med. 2000 Aug;6(8):623-44 - PubMed
    1. Oncogene. 2008 Feb 28;27(10):1345-54 - PubMed

MeSH terms

LinkOut - more resources